The impact of PSA testing frequency on prostate cancer incidence and treatment in older men

Y. H. Shao, P. C. Albertsen, W. Shih, C. B. Roberts, G. L. Lu-Yao

研究成果: 雜誌貢獻文章

15 引文 (Scopus)

摘要

To quantify the downstream impact of PSA testing on cancer characteristics and utilization of cancer therapies among men aged 70 or older, we utilized patients diagnosed with prostate cancer in 2004-2005 in the Surveillance, Epidemiology and End Results (SEER)-Medicare and their Medicare claims before their cancer diagnosis during 2000-2005. Among men in the highest testing group (4-6 PSA tests), 75% were diagnosed with low-or intermediate-risk of disease, but 77% received treatments within 180 days of cancer diagnosis. More than 45% of newly diagnosed patients in 2004-2005 had 4-6 PSA tests before their cancer diagnosis during 2000-2005. Men in the high testing group were 3.57 times more likely to receive cancer treatments (either surgery, radiation or hormonal therapy) when compared with men who had no previous PSA testing during the same time period. Among men aged 75 diagnosed with low-risk cancer, men in the high testing group were 78% more likely to receive treatment than those who had no previous PSA testing. In conclusion, given the lack of evidence of effective treatment for elderly patients diagnosed with low-and intermediate-risk prostate cancer and our inability to distinguish indolent from aggressive cancer, more frequent PSA testing among elderly population may exacerbate the risk of overdiagnosis and overtreatment.
原文英語
頁(從 - 到)332-339
頁數8
期刊Prostate Cancer and Prostatic Diseases
14
發行號4
DOIs
出版狀態已發佈 - 十二月 2011
對外發佈Yes

指紋

Prostatic Neoplasms
Incidence
Neoplasms
Therapeutics
Medicare
Epidemiology
Radiation
Population

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

引用此文

The impact of PSA testing frequency on prostate cancer incidence and treatment in older men. / Shao, Y. H.; Albertsen, P. C.; Shih, W.; Roberts, C. B.; Lu-Yao, G. L.

於: Prostate Cancer and Prostatic Diseases, 卷 14, 編號 4, 12.2011, p. 332-339.

研究成果: 雜誌貢獻文章

Shao, Y. H. ; Albertsen, P. C. ; Shih, W. ; Roberts, C. B. ; Lu-Yao, G. L. / The impact of PSA testing frequency on prostate cancer incidence and treatment in older men. 於: Prostate Cancer and Prostatic Diseases. 2011 ; 卷 14, 編號 4. 頁 332-339.
@article{e3c3df0f08b74e0aa662890435918f5a,
title = "The impact of PSA testing frequency on prostate cancer incidence and treatment in older men",
abstract = "To quantify the downstream impact of PSA testing on cancer characteristics and utilization of cancer therapies among men aged 70 or older, we utilized patients diagnosed with prostate cancer in 2004-2005 in the Surveillance, Epidemiology and End Results (SEER)-Medicare and their Medicare claims before their cancer diagnosis during 2000-2005. Among men in the highest testing group (4-6 PSA tests), 75{\%} were diagnosed with low-or intermediate-risk of disease, but 77{\%} received treatments within 180 days of cancer diagnosis. More than 45{\%} of newly diagnosed patients in 2004-2005 had 4-6 PSA tests before their cancer diagnosis during 2000-2005. Men in the high testing group were 3.57 times more likely to receive cancer treatments (either surgery, radiation or hormonal therapy) when compared with men who had no previous PSA testing during the same time period. Among men aged 75 diagnosed with low-risk cancer, men in the high testing group were 78{\%} more likely to receive treatment than those who had no previous PSA testing. In conclusion, given the lack of evidence of effective treatment for elderly patients diagnosed with low-and intermediate-risk prostate cancer and our inability to distinguish indolent from aggressive cancer, more frequent PSA testing among elderly population may exacerbate the risk of overdiagnosis and overtreatment.",
keywords = "medicare, PSA, SEER program, treatment",
author = "Shao, {Y. H.} and Albertsen, {P. C.} and W. Shih and Roberts, {C. B.} and Lu-Yao, {G. L.}",
year = "2011",
month = "12",
doi = "10.1038/pcan.2011.29",
language = "English",
volume = "14",
pages = "332--339",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - The impact of PSA testing frequency on prostate cancer incidence and treatment in older men

AU - Shao, Y. H.

AU - Albertsen, P. C.

AU - Shih, W.

AU - Roberts, C. B.

AU - Lu-Yao, G. L.

PY - 2011/12

Y1 - 2011/12

N2 - To quantify the downstream impact of PSA testing on cancer characteristics and utilization of cancer therapies among men aged 70 or older, we utilized patients diagnosed with prostate cancer in 2004-2005 in the Surveillance, Epidemiology and End Results (SEER)-Medicare and their Medicare claims before their cancer diagnosis during 2000-2005. Among men in the highest testing group (4-6 PSA tests), 75% were diagnosed with low-or intermediate-risk of disease, but 77% received treatments within 180 days of cancer diagnosis. More than 45% of newly diagnosed patients in 2004-2005 had 4-6 PSA tests before their cancer diagnosis during 2000-2005. Men in the high testing group were 3.57 times more likely to receive cancer treatments (either surgery, radiation or hormonal therapy) when compared with men who had no previous PSA testing during the same time period. Among men aged 75 diagnosed with low-risk cancer, men in the high testing group were 78% more likely to receive treatment than those who had no previous PSA testing. In conclusion, given the lack of evidence of effective treatment for elderly patients diagnosed with low-and intermediate-risk prostate cancer and our inability to distinguish indolent from aggressive cancer, more frequent PSA testing among elderly population may exacerbate the risk of overdiagnosis and overtreatment.

AB - To quantify the downstream impact of PSA testing on cancer characteristics and utilization of cancer therapies among men aged 70 or older, we utilized patients diagnosed with prostate cancer in 2004-2005 in the Surveillance, Epidemiology and End Results (SEER)-Medicare and their Medicare claims before their cancer diagnosis during 2000-2005. Among men in the highest testing group (4-6 PSA tests), 75% were diagnosed with low-or intermediate-risk of disease, but 77% received treatments within 180 days of cancer diagnosis. More than 45% of newly diagnosed patients in 2004-2005 had 4-6 PSA tests before their cancer diagnosis during 2000-2005. Men in the high testing group were 3.57 times more likely to receive cancer treatments (either surgery, radiation or hormonal therapy) when compared with men who had no previous PSA testing during the same time period. Among men aged 75 diagnosed with low-risk cancer, men in the high testing group were 78% more likely to receive treatment than those who had no previous PSA testing. In conclusion, given the lack of evidence of effective treatment for elderly patients diagnosed with low-and intermediate-risk prostate cancer and our inability to distinguish indolent from aggressive cancer, more frequent PSA testing among elderly population may exacerbate the risk of overdiagnosis and overtreatment.

KW - medicare

KW - PSA

KW - SEER program

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=80955151467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80955151467&partnerID=8YFLogxK

U2 - 10.1038/pcan.2011.29

DO - 10.1038/pcan.2011.29

M3 - Article

C2 - 21709691

AN - SCOPUS:80955151467

VL - 14

SP - 332

EP - 339

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 4

ER -